Skip to main content

Advertisement

SpringerLink
Log in

The Regulation of Companion Diagnostics: A Global Perspective

  • Global Perspectives
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

The emerging trend of validated biomarkers, otherwise known as companion diagnostics (CDx), is playing a key role in helping pharmaceutical companies acquire rapid regulatory approval of their targeted therapeutics while saving on development time and costs. In today’s challenging regulatory arena, diagnostics-led treatment can improve the reimbursement and market access for drugs. All of this has prompted research in the use of such biomarkers with targeted therapeutics for predicting response to therapy, hence beginning the revolution of personalized medicine. With the current target area being oncology, other therapeutic areas are also now being explored. As an increasing number of pharmaceutical firms are penetrating the CDx arena and looking to partner with diagnostics developers, this does not come without its challenges. The codevelopment process is complex, and many hurdles may need to be crossed before a perfect model can be achieved. To add further to the complexity, the global regulatory landscape for CDx is in a state of flux, making it extremely challenging for industry to keep up with the increasing demands of the regulators. This article provides an overview of the changing regulatory landscape for CDx in some of these key markets and an insight to deal with the challenges associated with developing a successful global regulatory strategy for a CDx product. The views presented in this article are mainly from a diagnostics perspective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mushiroda T. Advancing personalized medicine: tailoring drugs to fit a patient’s genetic predisposition. RIKEN Research. 2012;7(2). Available at: http://www.rikenresearch.riken.jp/eng/frontline/6945. Accessed February 24, 2013.

  2. Panel of Experts. Personalized health. Media Planet. September 2012: page 5.

  3. Challenges. Personalized health. Media Planet. September 2012: page 2.

  4. DOTmed News. A push for personalized medicine encourages new companion diagnostics. June 25, 2012. Available at: http://www.dotmed.com/news/story/19030?p_begin=0. Accessed February 24, 2013.

  5. Food and Drug Administration. Medical devices: in vitro companion diagnostic devices. Available at: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301-431.htm. Accessed June 1, 2013.

  6. Schofield I. Pulling out the stops on personalised medicine. RAJ Devices. December 9, 2010.

  7. Oregon Business News. U.S. health care spending to reach $13,710 per person by 2020, government says. Available at: http://www.oregonlive.com/business/index.ssf/2011/07/us_health_care_spending_to_rea.html. Accessed February 24, 2003.

  8. Rabiya ST. Economic analysis: big savings with KRAS testing. Oncology Times. 2009;31:42–43.

    Google Scholar 

  9. Food and Drug Administration. FDA draft guidance for industry and Food and Drug Administration staff: in vitro companion diagnostic devices. Available at: http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm262292.htm. Accessed February 17, 2013.

  10. Food and Drug Administration. FDA Code of Federal Regulations. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm. Accessed February 17, 2013.

  11. Food and Drug Administration. FDA draft guidance for industry and FDA staff: medical devices, the Pre-Submission program, and meetings with FDA staff. Available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm310375.htm. Accessed February 18, 2013.

  12. Rugnetta M. Commissioner enhances FDA’s commitment to personalized medicine. March 3, 2010. Available at: http://scienceprogress.org/2010/03/fda-personalized-medicine/. Accessed October 24, 2012.

  13. Insider Viewpoint. Foreign land mass compared to the United States. Available at: http://www.insidervlv.com/landmass.html. Accessed January 5, 2013.

  14. Trading Economics. Health expenditure, total (% of GDP) in Japan. Available at: http://www.tradingeconomics.com/japan/health-expenditure-total-percent-of-gdp-wb-data.html. Accessed October 24, 2012.

  15. Ministry of Health, Labor and Welfare of Japan. Home page. Available at: http://www.mhlw.go.jp/english/. Accessed February 17, 2013.

  16. Pharmaceuticals and Medical Devices Agency of Japan. Home page. Available at: http://www.pmda.go.jp/english/index.html. Accessed February 17, 2013.

  17. Emergo Group. MHLW Ministerial Ordinance No. 136. Available at: http://www.emergogroup.com/files/japan-mhlw-ordinance-136-english.pdf. Accessed February 17, 2013.

  18. Pharmaceuticals and Medical Devices Agency of Japan. MHLW Ministerial Ordinance No. 169. Available at: http://www.pmda.go.jp/english/service/pdf/ministerial/050909betsu3.pdf. Accessed February 17, 2013.

  19. Jingting S. Medical and healthcare investment soars. China Daily. November 5, 2011. Available at: http://www.chinadaily.com.cn/bizchina/2011-11/05/content_14042096.htm. Accessed October 24, 2012.

  20. State Food and Drug Administration of China. Regulations for the supervision and administration of medical devices. April 1, 2000. Available at: http://eng.sfda.gov.cn/WS03/CL0767/61641.html. Accessed February 17, 2013.

  21. State Food and Drug Administration of China. Home page. Available at: http://eng.sfda.gov.cn/WS03/CL0755/. Accessed February 17, 2013.

  22. State Food and Drug Administration of China. Order No. 229: circular on printing and issuing measures for the administration of in vitro diagnostic reagents. April 3, 2007. Available at: http://www.sfda.gov.cn/WS01/CL0059/9418.html. Accessed June 3, 2013.

  23. State Food and Drug Administration of China. Re-registration of import products: medical device registration. Available at: http://eng.sfda.gov.cn/WS03/CL0770/61660.html. Accessed April 21, 2013.

  24. Investment in a Quebec public-private partnership to support the use of personalized medicine solutions in the treatment of cancer patients. Oncology Link: Weekly Business and Scientific Insights. 2013;4(7):5.

  25. Health Canada. Home page. Available at: http://www.hc-sc.gc.ca/index-eng.php. Accessed February 17, 2013.

  26. Nguyen H, Vergara C. History of Canadian food and drug regulations. In: Diaz MS, ed. Fundamentals of Canadian Regulatory Affairs. 3rd ed. Rockville, Maryland: Regulatory Affairs Professionals Society; 2011:1.

    Google Scholar 

  27. Health Canada. Health Canada draft guidance: risk-based classification system of in vitro diagnostic devices. April 28, 1998. Available at: http://www.hc-sc.gc.ca/dhp-mps/md-im/applic-demande/guide-ld/ivd-rsk_idiv-rsq-eng.php. Accessed February 17, 2013.

  28. Health Canada. Health Canada draft guidance: preparation of Summary Technical Document (STED)–based class III and IV premarket in vitro diagnostic device licence applications and amendments. August 22, 2012. Available at: http://www.hc-sc.gc.ca/dhp-mps/consultation/md-im/consult_md_gd_data_im_ld_donnees_ciii_civ_ivdd_sted-eng.php. Accessed January 5, 2013.

  29. Health Canada. Health Canada guidance: preparation of a premarket review document for class III and class IV device licence applications V.2. Available at: http://www.hc-sc.gc.ca/dhp-mps/md-im/applic-demande/guide-ld/prmkt2_precomm2_main_principal-eng.php. Accessed February 24, 2013.

  30. International Medical Device Regulators Forum. GHTF SG1: Summary Technical Documentation (STED) for demonstrating conformity to essential principles of safety and performance of in vitro diagnostic medical devices. March 17, 2011. Available at: http://www.imdrf.org/search.asp?zoom_query=summary%20technical%20documentation. Accessed February 24, 2013.

  31. Health Canada. Policy on Canadian medical devices conformity assessment system. May 4, 2000. Available at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/md-im/cmdcas_scecim_syst_pol-eng.pdf. Accessed February 24, 2013.

  32. Health Canada. Submission of pharmacogenomic information. August 13, 2008. Available at: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/pharmaco/pharmaco_guid_ld-eng.php. Accessed February 24, 2013.

  33. Sarazzin P. Regulatory oversight of genetic testing in Canada. Health Canada Perspective. Available at: http://www.g-sin.com/pipelines/resource/6898_Sarrazin.pdf. Accessed February 24, 2013.

  34. Europa. In Vitro Diagnostic Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. October 27, 1998. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31998L0079:EN:NOT. Accessed February 17, 2013.

  35. Europa. European Commission proposal for the regulation of the European Parliament and of the Council on in vitro diagnostic medical devices: Brussels 26.9.2012. Available at: http://ec.europa.eu/health/medical-devices/files/revision_docs/proposal_2012_541_en.pdf. Accessed December 23, 2012.

  36. International Medical Device Regulators Forum. GHTF SG1: N045:2008 principles of IVD medical devices classification. July 31, 2008. Available at: http://www.imdrf.org/documents/doc-ghtf-sg1.asp. Accessed February 17, 2013.

  37. European Medicines Agency. Home page. Available at: http://www.ema.europa.eu/ema/. Accessed February 17, 2013.

  38. Europa. European Commission guidelines on a medical devices vigilance system: MEDDEV 2.12-1 rev8. January 2013. Available at: http://ec.europa.eu/health/medical-devices/files/meddev/2_12_1_ol_en.pdf. Accessed February 24, 2013.

  39. International Medical Device Regulators Forum. GHTF guidance on how to handle information concerning vigilance reporting related to medical devices: GHTF/SG2/N008R4. June 29, 1999. Available at: http://www.imdrf.org/docs/ghtf/final/sg2/technical-docs/ghtf-sg2-n008r4-reporting-guidance-990629.pdf. Accessed January 5, 2013.

  40. Food and Drug Administration. Unique device identification (UDI). Available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/UniqueDeviceIdentification/default.htm. Accessed February 18, 2013.

  41. Gross TP, Crowley J. Unique device identification in the service of public health. N Engl J Med. 2012;367(17):1583–1585.

    Article  CAS  Google Scholar 

  42. Regulatory Affairs Professionals Society. IMDRF issues major guidance outlining UDI framework for medical devices. RAPS Regulatory Focus. April 17, 2013. Available at: http://www.raps.org/focus-online/news/news-article-view/article/3198/imdrf-issues-major-guidance-outlining-udi-framework-for-medical-devices.aspx. Accessed April 21, 2013.

  43. Next Generation Pharmaceutical. The commercialization of companion diagnostics. Clinical Research: Issue 12. Available at: http://www.ngpharma.com/article/The-commercialization-of-companion-diagnostics/. Accessed April 21, 2013.

  44. Schulman KA, Sean RT. A policy approach to the development of molecular diagnostic tests. Nature Biotechnology. 2010;28(11):1157–1159.

    Article  CAS  Google Scholar 

  45. Ray T. AMA threatens to file HIPAA complaint unless CMS halts program requiring Z-Codes for MDx tests. Pharmacogenomics Reporter. January 4, 2012. Available at: http://www.genomeweb.com/mdx/ama-threatens-file-hipaa-complaint-unless-cms-halts-program-requiring-z-codes-md. Accessed June 1, 2013.

Download references

Author information

Authors and Affiliations

  1. OptumInsight Inc (UnitedHealth Group), 4 Innovation Drive, Dundas, ON, L9H 7P3, Canada

    Maham Ansari MS, RAC

Authors
  1. Maham Ansari MS, RAC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maham Ansari MS, RAC.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ansari, M. The Regulation of Companion Diagnostics: A Global Perspective. Ther Innov Regul Sci 47, 405–415 (2013). https://doi.org/10.1177/2168479013492734

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479013492734

Keywords

Search

Navigation